Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Open-Label, Sequential Dose Escalation Study Investigating the Safety, Tolerability, and Pharmacokinetics of Intravenous Lipotecan® (TLC388 HCl for Injection) When Administered to Patients With Advanced Solid Tumors

NCT00747474 is registered in ClinicalTrials.gov with Taiwan Liposome Company as lead sponsor.

NCT NCT00747474
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00747474 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Open-Label, Sequential Dose Escalation Study Investigating the Safety, Tolerability, and Pharmacokinetics of Intravenous Lipotecan® (TLC388 HCl for Injection) When Administered to Patients With Advanced Solid Tumors
Lead sponsor
Taiwan Liposome Company
Phase
Phase 1
Overall status
Completed
Start date
September 30, 2008
Completion date
December 31, 2011
Enrollment
54 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors